Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Anemia is a common complication among the patients with end-stage kidney disease (ESKD) and poses an enormous economic burden to health-care systems. Recent studies has shown that online hemodiafiltration (OL-HDF) can reduce the amount of erythropoiesis-stimulating agents (ESAs) and improve anemia management when compared to hemodialysis (HD).
The objectives of this study were to evaluate the effects of post-dilution OL-HDF on anemia-related parameters and ESA resistance in comparison with high-flux hemodialysis (HF-HD).
This is retrospective cohort study including 4261 incident OL-HDF and HF-HD patients treated in 40 Diaverum clinics in Saudi Arabia between January 2022 to December 2024. Among them, 1319 (31%) received post-dilution online OL-HDF and 2942 (69%) received HF-HD over a 3 years-period. Measurements of various anemia-related parameters were collected during HF-HD and post-dilution OL-HDF periods for statistical analysis for erythropoietin (EPO) resistance index (ERI). The courses of hemoglobin levels (Hb) and ESA consumption were compared between the two groups every 6 months and during 3 years. Comparisons were made using Mann–Whitney and chi-square tests. Significance was defined at p < 0.05.
Across all time intervals, post dilution OL-HDF patients consistently required lower EPO doses (mean 62–71 vs. 75–81 IU/kg/week in HD; p < 0.001) and demonstrated lower ERI values (7.1–8.2 vs. 8.0–8.6; p < 0.01), confirming enhanced erythropoietin responsiveness. Iron supplementation remained comparable between modalities (31–43 mg/week; p > 0.05), indicating similar iron utilization efficiency. Despite reduced EPO exposure, OL-HDF achieved higher mean hemoglobin levels (11.07 ± 0.90 vs. 10.94 ± 0.94 g/dL; p < 0.001).
Target hemoglobin range (10–12 g/dL) was reached in 93.3% of post-dilution OL-HDF versus 92.3% of HF-HD patients (p = 0.046), while sub-target Hb <10 g/dL occurred less frequently in OL-HDF (5.5% vs. 7.3%; p = 0.038). Overcorrection >12 g/dL remained rare (1.1% vs. 0.5%; p = 0.049).
Collectively, these findings highlight that post-dilution OL-HDF achieved equivalent or superior hemoglobin targets with lower erythropoietin exposure, without increasing iron requirements.
Over a 36-month follow-up, patients maintained on online HDF demonstrated significantly lower EPO dosing and ERI values, with comparable iron supplementation and better hemoglobin stability compared to high-flux HD. Results of our retrospective study suggest that patients on post dilution OL-HDF may have clinical benefits in terms of anemia management. Future prospective randomized studies are needed to confirm our results and to provide additional evidence on the potential beneficial effects of OL-HDF.
